MSB-3163 is under clinical development by Matrisys Bioscience and currently in Phase I for Acne Vulgaris. According to GlobalData, Phase I drugs for Acne Vulgaris have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MSB-3163’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MSB-3163 overview

MSB-3163 is under development for the treatment of acne. The therapeutic candidate comprises beneficial bacteria.

Matrisys Bioscience overview

Matrisys Bioscience is a biopharmaceutical company. It focuses to develop and commercialize microbiome therapies for dermatology and skin care conditions. The company’s lead programs includes MSB-01, a topical antimicrobial live biotherapeutic product that is being developed for the treatment of atopic dermatitis which is rapidly advancing therapeutics; MSB-02, for bacterial infections; and MSB-03 for netherton syndrome, psoriasis and rosacea. It works in collaboration with the pharmaceutical companies to research and develop its product portfolio. Matrisys Bioscience is headquartered in San Diego, California, the US.

For a complete picture of MSB-3163’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.